The Pan-Drug Resistant (PDR),
Helicobacter pylori
remains an intractable challenge in public health worldwide and this pathogenicity is mainly due to the presence of a cytotoxin-associated gene A (CagA) and vacuolating cytotoxin A (VacA). On the other hand, plant extracts such as
Syzygium aromaticum
contain a diverse array of secondary metabolites, which could be potentially used to combat
H. pylori
pathogens. To our knowledge, this is the first report on the biomedical potential of
S. aromaticum
extract against cytotoxin-associated genes producing PDR
H. pylori
. In this investigation, out of 45 gastric antral biopsy specimens of dyspeptic patients, 20 strains were confirmed as
H. pylori.
Eight (40%) out of 20 strains were PDR
H. pylori
while the rest of the strains were Multi-Drug Resistant (MDR) strains. Genotypic analyses of PDR
H. pylori
strains showed that
cagA
and
vacA
genes were found to be 75% and 87.5%, respectively and
m2s2
was the most common subtype of
vacA
gene.
S. aromaticum
showed a significant higher anti-
H. pylori
activity compared to that of
Cinnamomum zeylanicum
and
Thymus vulgaris
. Eugenol was the major phenolic compound (28.14%) detected in the methanolic extract of
S. aromaticum
. Clearly, results of the toxicological assessment confirmed the safety of
S. aromaticum
for use. Hence, these results suggest that
S. aromaticum
could be a new useful natural antimicrobial agent that could potentially combat cytotoxin genes-producing drug-resistant
H. pylori
. Moreover, these findings provide a scientific basis for the development of antimicrobial agents from traditional herbal medicines for gastroprotection against gastric ulcer.